Clinical trials · California
Metastatic Lung Non-Small Cell Carcinoma clinical trials in California
We’re tracking 82 recruiting metastatic lung non-small cell carcinoma studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Sacramento, CaliforniaAges 18 years+ - NCT06910761RecruitingPhase 2
Radiation for cancer spread to brain lining
This trial tests whether a precise type of radiation to the brain and spine (craniospinal irradiation) can help control cancer that has spread to the lining of the brain and spinal cord (leptomeningeal disease) in people with breast cancer or non-small cell lung cancer. The goal is to improve symptoms and slow disease progression.
Duarte, CaliforniaAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Long Beach, CaliforniaAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Fullerton, CaliforniaAges 18 years+ - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
La Mesa, CaliforniaAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Clovis, CaliforniaAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Alameda, CaliforniaAges 18 years+ - NCT06758401RecruitingPhase 3
Study of combination treatment for advanced lung cancer with high PD-L1
This trial tests a new combination of two medicines (sigvotatug vedotin and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has high levels of a protein called PD-L1. The treatment is designed to help your immune system fight the cancer more effectively, and this study aims to see how well it works.
Fullerton, CaliforniaAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Irvine, CaliforniaAges 18 years+ - NCT06686771RecruitingPhase 3
Radiation for limited growth in advanced lung cancer on immunotherapy
This trial tests whether giving high-precision radiation to a few spots that are growing during immunotherapy (with or without chemotherapy) can help people with advanced lung cancer. It aims to see if treating these limited areas of resistance can extend the time the cancer stays under control.
Duarte, CaliforniaAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Los Alamitos, CaliforniaAges 18 years+ - NCT06518057RecruitingPhase 2
Sparing memory during brain radiation for leptomeningeal metastases
This trial tests a special type of radiation that avoids the memory center of the brain (the hippocampus) while treating cancer that has spread to the lining of the brain and spinal cord. It may help reduce side effects on thinking and memory for people with breast or lung cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06500481RecruitingPhase 3
Proton vs standard radiation for cancer spread to brain/spine lining
This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.
Encinitas, CaliforniaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT06444815RecruitingPhase 1
Study of VET3-TGI for advanced solid tumors
This trial tests an experimental treatment called VET3-TGI, which is injected directly into tumors. It is for people with advanced solid tumors who have already tried other treatments and are looking for new options.
Orange, CaliforniaAges 18 years+ - NCT06427941RecruitingPhase 1/Phase 2
Study of BGB-B2033 with other drugs for advanced solid tumors
This study tests a new drug called BGB-B2033, alone or with other drugs (tislelizumab and bevacizumab), in people with certain advanced cancers. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
Duarte, CaliforniaAges 18 years+ - NCT06343402RecruitingPhase 1
Study of BBO-8520 for advanced KRAS G12C lung cancer
This trial tests a new oral medication called BBO-8520 for advanced lung cancer with a specific gene change (KRAS G12C mutation). It aims to see if the drug is safe and effective, and may be combined with another drug (pembrolizumab) in some groups.
La Jolla, CaliforniaAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT06249282RecruitingPhase 1
Carfilzomib and sotorasib for KRAS G12C lung cancer
This trial tests a combination of two drugs: carfilzomib and sotorasib, for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have already tried a KRAS-targeting drug that stopped working. The goal is to see if this new combination can shrink tumors or slow the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Newport Beach, CaliforniaAges 18 years+ - NCT06216301RecruitingPhase 3
Electric fields with immunotherapy and chemo for advanced lung cancer
This trial tests adding a device that delivers electric fields (Tumor Treating Fields) to standard immunotherapy and chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. It may help slow tumor growth.
Fullerton, CaliforniaAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+
Metastatic Lung Non-Small Cell Carcinoma trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting metastatic lung non-small cell carcinoma studies listed above.
- City of Hope · 8 studies
- City of Hope at Irvine Lennar · 3 studies
- Providence Medical Foundation · 3 studies
- University of California San Diego Moores Cancer Center · 3 studies
- University of California, San Francisco · 3 studies
- California Pacific Medical Center · 2 studies
- Hoag Memorial Hospital Presbyterian · 2 studies
- Research Site · 2 studies
What taking part in a metastatic lung non-small cell carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Lung Non-Small Cell Carcinoma trials in other states
Common questions
- Are there metastatic lung non-small cell carcinoma clinical trials in California?
- Yes. We're currently tracking 82 recruiting metastatic lung non-small cell carcinoma studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic lung non-small cell carcinoma study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic lung non-small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic lung non-small cell carcinoma studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.